Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of Risankizumab in Psoriatic Arthritis
2016-003113-94Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in psoriatic arthritis (PsA), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of risankizumab. Started Sep 2016; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-003113-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003113-94.